Search clinical trials for: FAITH! App

Total 4458 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IVA Oropharyngeal Carcinoma AJCC v7 | Stage IVB Oropharyngeal Carcinoma AJCC v7

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditions

United States
University of Washington
Bayer

Terminated

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Non-Hodgkin's Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Grade 3b Follicular Lymphoma

United States
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
St. Jude Children's Research Hospital
Assisi Foundation; Cookies for Kids' Cancer

Completed

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood B-Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Non-Neoplastic Hematologic and Lymphocytic Disorder

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

United States, Canada, Australia, New Zealand
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements

United States
M.D. Anderson Cancer Center

Withdrawn

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Malignant Glioma | Medulloblastoma | Anaplastic Ependymoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Atypical Teratoid/Rhabdoid Tumor | Primitive Neuroectodermal Tumor | Choroid Plexus Carcinoma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Malignant Brain Neoplasm | Central Nervous System... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Desmoplastic Small Round Cell Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Ewing Sarcoma/Peripheral... and other conditions

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; City of Hope National Medical Center and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Metastatic Melanoma | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Active, not recruiting

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Lymphoblastic Lymphoma | Childhood Acute Myeloid Leukemia in Remission | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States, Canada, Australia, New Zealand, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand
Fred Hutchinson Cancer Center
National Cord Blood Network

Recruiting

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Chronic...

United States
National Cancer Institute (NCI)

Not yet recruiting

MyeloMATCH MSRP: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study

Acute Myeloid Leukemia | Myelodysplastic Syndrome
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Ph-Like Acute Lymphoblastic Leukemia | Refractory Ph-Like Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Completed

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Canada, Australia, New Zealand, Puerto Rico
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation

Active, not recruiting

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Fred Hutchinson Cancer Center

Withdrawn

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Recurrent Hodgkin Lymphoma | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Recurrent... and other conditions

United States
CM Chungmu Hospital
Korea United Pharm. Inc.

Unknown

Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting

Nausea | Vomiting

Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm | Chronic Myelomonocytic Leukemia-2 | Blasts 10 Percent or More of Bone Marrow Nucleated... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
National Cancer Institute (NCI)

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

United States, Puerto Rico, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia in Remission

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico

Search clinical trials for: FAITH! App

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations